Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
57results about How to "Limited efficacy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
Owner:EDUSA PHARMA
Modified vaccinia Ankara expressing p53 in cancer immunotherapy
ActiveUS7256037B2Limit therapeutic efficacyReduce developmentBiocideGenetic material ingredientsModified vaccinia AnkaraADAMTS Proteins
Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy. Unfortunately, p53 is an autoantigen that is likely to be tolerated as a self-protein by the immune system. The present invention is based on the discovery that this self-tolerance can be overcome by administration of recombinant modified vaccinia Ankara (MVA) containing a nucleic acid that encodes p53 (rMVAp53). The invention discloses a method of generating a p53-specific CTL-response to tumor cells expressing mutated p53 by administering a composition comprising rMVAp53. Administration of rMVAp53 decreases tumor development, tumor growth, and mortality in a variety of malignant cell types. These effects are enhanced by administration of CTLA-4 blocker and / or CpG oligodeoxynucleotide immunomodulators.
Owner:CITY OF HOPE
Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
InactiveUS20060247311A1Need lessLimited efficacyBiocidePeptide/protein ingredientsDiseaseGabapentinoid
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and / or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Method and apparatus for acoustic crosstalk cancellation
ActiveUS20170257725A1Cancel impactLess cancellationSignal processingTwo-channel systemsCrosstalk cancellationLoudspeaker
An acoustic crosstalk canceller is determined for an asymmetric audio playback device, by determining a transfer function of an acoustic stereo playback path having asymmetries defined by speakers of the playback device. The transfer function is inverted to determine an inverse transfer function. The inverse transfer function is regularised by applying frequency dependent regularisation parameters to obtain an acoustic crosstalk canceller. Also, the inverse transfer function could be regularised for symmetric playback paths by applying aggregated frequency dependent regularisation parameters to obtain an acoustic crosstalk canceller without band branching.
Owner:CIRRUS LOGIC INC
Low-melting biocidal formulation
ActiveUS8252819B2Prevent rapid leachingWide variationBiocideDead animal preservationRoom temperatureHydroxybenzoate
Owner:ROHM & HAAS CO
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
ActiveUS20120088764A1Effective for treating diseaseHigh activityOrganic active ingredientsNervous disorderDiseaseHistone deacetylase
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
Owner:CURIS INC
Targeted nanovectors and their use for treatment of brain tumors
InactiveUS20140154269A1Efficient killingEfficient deliveryHeavy metal active ingredientsPeptide/protein ingredientsNanocarriersActive agent
In some embodiments, the invention pertains to therapeutic compositions for treating a brain tumor. Such therapeutic compositions generally comprise: (1) a nanovector; (2) an active agent associated with the nanovector with activity against brain tumor cells; and (3) a targeting agent associated with the nanovector with recognition activity for a marker of the brain tumor cells. In some embodiments, the active agent and the targeting agent are non-covalently associated with the nanovector. Additional embodiments of the present invention pertain to methods of treating a brain tumor in a subject (e.g., a human being) by administering the aforementioned therapeutic compositions to the subject. Further embodiments of the present disclosure pertain to methods of formulating therapeutic compositions for treating a brain tumor in a subject in a personalized manner.
Owner:THE METHODIST HOSPITAL RES INST +1
Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
ActiveUS8710219B2Maintain good propertiesPotent antiproliferative activityOrganic active ingredientsOrganic chemistryHistone deacetylaseZinc binding
The invention provides a compound of Formula I,Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
Owner:CURIS INC
Systems and methods for cryptographically-secure queries using filters generated by multiple parties
ActiveUS10235335B1Accurately determineImprove relevanceDatabase updatingDigital data protectionPlaintextCiphertext
Systems and methods that permit the querying of encrypted data in a cryptographically-secure manner. Generally, data that has been encrypted cannot be queried using plaintext terms because it is in ciphertext. Accordingly, use of filters that correspond to the encrypted data and are generated by multiple parties permits querying of the data without decrypting the data or compromising the security of the encrypted data or of the queries against that data.
Owner:IONIC SECURITY
Systems and methods for generation of secure indexes for cryptographically-secure queries
ActiveUS10740474B1Limited efficacyReduce usageUser identity/authority verificationDigital data protectionTheoretical computer scienceTree (data structure)
Systems and methods are disclosed for generation of secure indexes that permit the querying or searching of encrypted data in a cryptographically-secure manner. In various embodiments, a filter gradient comprises a node identifier, a set membership filter, and an ordered genealogy (such that it comprises a filter that encodes a subset of the items encoded by its parent), and a FiG tree is a rooted tree with filter gradients (and, optionally, one or more dictionaries) as nodes such that each filter gradient uses a different hash. A HiiT data structure, in various embodiments, comprises a hash table that points to the rows of an inverted index table. In various embodiments, an oblivious pseudorandom function may be employed to mask, secure, and prepare the phrases for insertion into the secure indexes.
Owner:IONIC SECURITY
Combination Therapy
ActiveUS20150004179A1Minimizing progressionLonger and greater exposure to cell surface P2XSnake antigen ingredientsCancer antigen ingredientsBody fluidCombination therapy
Owner:BIOSCEPTRE PTY LTD
HIV protease inhibitors and methods for using
InactiveUS8501961B2Marked potency in enzyme inhibitory and cell culture assaysImprove life expectancyBiocideCarbamic acid derivatives preparationProteinase activityImmunodeficiency virus
Compounds that inhibit proteolytic enzymes of Human Immunodeficiency Virus (HIV) are described. Preparation of the inhibitors, pharmaceutical compositions containing them, and uses of the compounds or compositions for the treatment of HIV infections are also described.
Owner:PURDUE RES FOUND INC
Method of increasing endogenous adiponectin production and leptin production
InactiveUS20070203225A1Improve the level ofLimited efficacyBiocideAnimal repellantsAdiponectin secretionSecretion
A formulation for and method of enhancing adiponectin and leptin secretion is disclosed. The method comprises contacting living cells with an inhibitor of the enzyme pyruvate dehydrogenase kinase (PDHK). The PDHK inhibitor causes the cells it contacts to increase adiponectin secretion as well as increasing the production of leptin. The increased levels of adiponectin alone (or in a synergistic combination with increased leptin) provides a range of desired results including weight loss and the prevention of weight.
Owner:RGT UNIV OF CALIFORNIA +1
Growth inhibitory effects of nanoparticles containing triterpene glycosides or triterpenes
InactiveUS20130177627A1Overcome toxicityDramatic incidencePowder deliveryOrganic active ingredientsGlycosideTriterpene
The present invention relates to pharmaceutical composition containing a physiologically effective dose of a nanoparticle triterpene glycoside or nanoparticle triterpene complex, wherein said complex is a liposome encapsulated compound, or exosome-encapsulated compound.
Owner:RES FOUND THE CITY UNIV OF NEW YORK
C-rel inhibitors and uses thereof
ActiveUS20150218109A1Limited efficacyBlock Rel activationAntibacterial agentsOrganic active ingredientsHalogenNitrogen
Compounds having a c-Rel inhibiting property according to the formula: (1) wherein R1 and R2 are each independently selected from hydrogen atom and hydrocarbon groups having at least one and up to thirty carbon atoms and optionally substituted with one or more heteroatoms selected from halogen, nitrogen, oxygen, and sulfur; R3 is selected from hydrocarbon groups having at least one and up to thirty carbon atoms and optionally substituted with one or more heteroatoms selected from halogen, nitrogen, oxygen, and sulfur; and X1, X2, and X3 are each independently selected from oxygen and sulfur atoms. Methods for treating diseases and conditions associated with c-Rel overexpression by administering compounds of Formula (1) or a pharmaceutical composition thereof to a subject afflicted with such a disease or condition are also described.
Owner:CORNELL UNIVERSITY
Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
ActiveUS20130090335A1Maintain good propertiesPotent antiproliferative activityOrganic active ingredientsOrganic chemistryHistone deacetylaseZinc binding
The invention provides a compound of Formula I,Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
Owner:CURIS INC
Methods for treating functional bowel disorders using alpha2 subunit calcium channel modulators with smooth muscle modulators
InactiveUS20060276542A1Limited efficacyReduce patient complianceBiocidePeptide/protein ingredientsGabapentinoidAdrenergic receptor agonists
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or, more compounds with smooth muscle modulatory effects to treat functional bowel disorders in patients in need of treatment. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs including gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Low-melting biocidal formulation
ActiveUS20090258916A1Prevent rapid leachingWide variationBiocideDead animal preservationChemical compositionRoom temperature
A low-melting biocidal composition comprising 4,5-dichloro-2-octyl-3(2H)-isothiazolone, 3-iodopropargyl-N-butyl carbamate and at least one C1-C4 alkyl 4-hydroxybenzoate. The composition is stable with regard to agglomeration and crystallization at room temperature.
Owner:ROHM & HAAS CO
Combination therapy
ActiveUS9566318B2Minimizing progressionLonger and greater exposure to cell surface P2XPeptide/protein ingredientsCancer antigen ingredientsCombination therapyCancer
Owner:BIOSCEPTRE PTY LTD
Time temperature monitoring system
ActiveUS20160372391A1Limited efficacyThermometers using mean/integrated valuesThermometers using value differencesEngineeringDiffusion
A time temperature monitoring system and method for use with a microchip or similar structure. A disclosed system includes: a substrate having an active region; a dopant source located proximate the active region; an activation system for activating a diffusion of the dopant source into the active region; and a set of spatially distributed electrodes embedded in the active region of the substrate, wherein the electrodes are configured to detect the diffusion in the active region at varying distances from the dopant source to provide time temperature information.
Owner:IBM CORP
Synergistic 5′-methylthioadenosine combinations
InactiveUS8236778B2Reduce harmful effectsPotent immunomodulatory activityBiocideNervous disorderAdenosineEthylic acid
Owner:PROYECTO DE BIOMEDICINA CIMA
Artificially designed pore-forming proteins with anti-tumor effects
InactiveUS20050256040A1Limited anti-tumor effectModerate efficacyPeptide/protein ingredientsAntineoplastic agentsAbnormal tissue growthCell membrane
Protein engineering is an emerging area that has expanded the understanding in the art of protein folding and laid the groundwork for the creation of unprecedented structures with unique functions. The first native-like pore-forming protein, small globular protein (SGP), has previously been designed. It has now been discovered that this artificially engineered protein, and analogs and homologs thereof, have membrane-disrupting properties and anti-tumor activity in several cancer animal models. A mechanism for the selectivity of SGP toward cell membranes in tumors is proposed and validated herein, thereby confirming the proposed mechanism of action. Thus, SGP is established herein as the prototype for a new class of artificial proteins designed for therapeutic applications.
Owner:THE BUCK INST FOR RES ON AGING
Synergistic 5'-methylthioadenosine combinations
InactiveUS20110015132A1Potent immunomodulatory activityReduce harmful effectsBiocideNervous disorderGlatiramer acetateEndocrinology
The present invention relates to combinations of 5′-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5′-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and / or treatment of multiple sclerosis.
Owner:PROYECTO DE BIOMEDICINA CIMA
Systems and methods for cryptographically-secure queries using filters generated by multiple parties
ActiveUS10503730B1Limited efficacyEfficient representationDatabase updatingDigital data protectionPlaintextCiphertext
Systems and methods that permit the querying of encrypted data in a cryptographically-secure manner. Generally, data that has been encrypted cannot be queried using plaintext terms because it is in ciphertext. Accordingly, use of filters that correspond to the encrypted data and are generated by multiple parties permits querying of the data without decrypting the data or compromising the security of the encrypted data or of the queries against that data.
Owner:IONIC SECURITY
Mesenchymal stromal cells for treating sepsis
InactiveUS20170151284A1Improve survivalLimited efficacyAntibacterial agentsPowder deliveryStromal cellMesenchymal stem cell
Owner:TIGENIX SAU
Low-frequency compact air-cavity electrodeless high intensity discharge lamps
ActiveUS9754777B1Improve performanceImprove efficiencyCircuit arrangementsElectric lighting sourcesEngineeringHigh intensity
Electrodeless high intensity discharge lamps have the promise of higher reliability and higher efficiency than traditional electroded high intensity discharge lamps. However most electrodeless HIDs operate in the frequency range of around 400 MHz to 2.5 GHz resulting in expensive, inefficient RF drivers that reduce the overall efficacy of the lamp. Operating the lamp at lower frequencies results in substantial increase in the size of the resonators used in traditional electrodeless HIDs. In this invention a novel design is used to lower the operating frequency of the resonator without increasing the size of the resonator. This provides an avenue to increase the conversion efficiency of the RF driver and the efficacy of the lamp system.
Owner:AMPLIQA INC
Heparanase expression in human t lymphocytes
InactiveUS20160017302A1Good curative effectImproving trafficking and survivalBiocideGenetic material ingredientsCancer cellLymphocyte
Embodiments of the present disclosure concern improvements to cell therapy for cancer. In certain embodiments, an ex vivo expanded T cell lacks endogenous heparanase expression, and amelioration of this effect allows an improvement for cancer cell therapy, including of solid tumors. In specific embodiments, ex vivo expanded T cells comprise recombinant heparanase expression.
Owner:BAYLOR COLLEGE OF MEDICINE
Method of increasing endogenous adiponectin and leptin production
InactiveUS20050261362A1Increase insulin sensitivityReduce fat depositionBiocideHydroxy compound active ingredientsAdiponectin secretionSecretion
A formulation for and method of enhancing adiponectin and leptin secretion is disclosed. The method comprises contacting living cells with an inhibitor of the enzyme pyruvate dehydrogenase kinase (PDHK). The PDHK inhibitor causes the cells it contacts to increase adiponectin secretion as well as increasing the production of leptin. The increased levels of adiponectin alone (or in a synergistic combination with increased leptin) provides a range of desired results including weight loss and the prevention of weight.
Owner:RGT UNIV OF CALIFORNIA +1
Compounds and methods for treating aids and HIV infections
ActiveUS20120059161A1Improve life expectancyImprove the quality of lifeOrganic chemistryCarbamateTherapy HIV
Macrocycle containing carbamate compounds that inhibit HIV proteolytic enzymes and processes for preparing them are described. Compositions and methods for treating a patient infected with HIV are described.
Owner:PURDUE RES FOUND INC
Sofflower injection and its prepn. method
A safflower injection with high curative effect is prepared from fresh safflower through cold storage in nitrogen gas, reflux seeping by the aqueous solution of alcohol, filter, concentrating, treating it by petroleum ether, removing petroleum ether and conventionally preparing injection.
Owner:王锋
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com